MILLIPLEX^® Human Complement Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: Adipsin/Factor D, C2, C4b, C5, C5a, C9, Factor I, MBL, Properdin

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

The complement system consists of a large number of plasma proteins that assist, or complement, the ability of phagocytic cells and antibodies to clear pathogens. Although it is part of the innate immune system, not adaptable and unchanging over the course of a lifetime, it can be recruited and activated by the adaptive immune system. The system proteins and glycoproteins that are synthesized primarily by hepatocytes normally circulate as inactive pro-proteins. Once stimulated the end result of the cascade is a massive amplification of response and activation of the membrane attack complex, which forms a transmembrane pore causing osmotic lysis of target cells. The complement system consists of three different simultaneous pathways. The classical pathway is stimulated by antigen-antibody complexes; the alternative pathway spontaneously activates on contact with pathogenic cell surfaces; the mannose-binding lectin pathway recognizes mannose sugars usually present only on pathogenic cell surfaces. The complement system is thought to play a key role in many diseases with an immune component, such as asthma or sepsis, and in many autoimmune diseases, including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. It is also becoming increasingly associated with neurological diseases, such as Alzheimer′s Disease, and conditions such as spinal cord injuries.